<DOC>
	<DOCNO>NCT02297594</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability PK single multiple ascend dose AK0529 administer orally healthy subject</brief_summary>
	<brief_title>Safety , Tolerability PK Study AK0529 Healthy Human</brief_title>
	<detailed_description>This Phase 1 , first-in-man , single-center , randomize , double blind , placebo control single multiple ascend dose study healthy male female volunteer .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1 . Must healthy male , healthy female nonchildbearing potential surgically sterilize postmenopausal ( amenorrhea least 1 year confirm follicle stimulate hormone [ FSH ] result &gt; 20 IU/mL ) . 2 . Must age 18 55 year age inclusive . 3 . Must body mass index ( BMI ) 18.0 31.0 kg/m2 inclusive . 4 . Must total body weight ≥50 kg screen ≤100 Kg . 5 . Must willing able communicate participate whole study . 6 . Must provide write informed consent . 7 . Must agree use adequate method contraception ( defined Section 4.2.1 ) . 8 . Must AST , ALT , total bilirubin , urea , creatinine hemoglobin within laboratory reference range screen Day 1 . 9 . Must QTcF &lt; 450 m , QTcB &lt; 450 m PR interval &lt; 210 m screening , Day 1 predose ECG measurement , degree heart block conduction abnormality . 10 . Must serology demonstrate free infection hepatitis B , hepatitis C , human immunodeficiency virus ( HIV1 HIV2 ) 1 . Male subject currently pregnant partner partner plan become pregnant duration study . 2 . Evidence history clinical significant oncological , pulmonary , chronic respiratory , hepatic , cardiovascular , hematological , metabolic , neurological , immunological , nephrological , endocrine psychiatric disease , current infection . 3 . Clinically relevant ( decided investigator medical monitor ) abnormalities ECG ( 12 standard lead ) include degree heart block , include asymptomatic bundle branch block . 4 . Family history sudden death congenital prolongation QTc interval know congenital prolongation QTc interval clinical condition know prolong QTc interval . 5 . History symptomatic cardiac arrhythmia clinically relevant bradycardia . 6 . Electrolyte disturbance , particularly hypokalemia hypocalcemia hypomagnesemia . 7 . Any condition could possibly affect drug absorption , e.g . gastrectomy diarrhea . 8 . History postantibiotic colitis . 9 . History drug alcohol abuse past 2 year prior screen . 10 . Regular alcohol consumption male &gt; 21 unit per week female &gt; 14 unit per week ( 1 unit = 400 mL beer , 25 mL 40 % spirit 75 mL glass wine ) . 11 . Subjects urine cotinine great 500 ng/mL screening exclude . Subjects tobacco user ( include smoker user snuff , chew tobacco nicotine nicotinecontaining product ) must stop use least 90 day screen . 12 . Receipt investigational drug participation another clinical research study within 90 day prior drug administration . 13 . Subjects study site employee , immediate family member study site sponsor employee . 14 . Subjects previously enrol dosed study , except subject undergo repeat dose Cohort 4F ( feed PK cohort SAD part study ) . Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>